Cencora Reports Q2 2026 Earnings and Updates Fiscal Outlook
Cencora reported solid operating income growth in both U.S. and International segments despite revenue challenges from manufacturer price cuts and customer losses. The company raised its full-year EPS guidance to $17.65–$17.90, citing strong performance and share repurchase plans.
Tickers: $COR
Topics: divestitures operational performance pharmaceuticals share buybacks